BridgeBio Pharma [BBIO] vs Regeneron [REGN] Detailed Stock Comparison

BridgeBio Pharma

NASDAQ
Loading...

Regeneron

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: BridgeBio Pharma wins in 8 metrics, Regeneron wins in 10 metrics, with 0 ties. Regeneron appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricBridgeBio PharmaRegeneronBetter
P/E Ratio (TTM)-18.3515.13BridgeBio Pharma
Price-to-Book Ratio-5.662.09BridgeBio Pharma
Debt-to-Equity Ratio-1.049.04BridgeBio Pharma
PEG Ratio-0.13-200.46Regeneron
EV/EBITDA-17.9812.86BridgeBio Pharma
Profit Margin (TTM)98.25%31.37%BridgeBio Pharma
Operating Margin (TTM)-120.72%29.64%Regeneron
EBITDA Margin (TTM)N/A29.64%N/A
Return on Equity36.76%15.34%BridgeBio Pharma
Return on Assets (TTM)-41.96%6.66%Regeneron
Free Cash Flow (TTM)$-529.63M$3.54BRegeneron
Dividend YieldN/A0.46%N/A
1-Year Return110.85%-42.36%BridgeBio Pharma
Price-to-Sales Ratio (TTM)42.854.47Regeneron
Enterprise Value$11.22B$57.45BRegeneron
EV/Revenue Ratio47.564.04Regeneron
Gross Profit Margin (TTM)96.70%85.58%BridgeBio Pharma
Revenue per Share (TTM)$1$133Regeneron
Earnings per Share (Diluted)$-4.13$39.66Regeneron
Beta (Stock Volatility)1.360.31Regeneron
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

BridgeBio Pharma vs Regeneron Stock Performance Analysis

Loading Price Chart...

BridgeBio Pharma
Regeneron
BridgeBio Pharma Stock Overview | Regeneron Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
BridgeBio Pharma3.31%5.10%0.59%25.54%78.06%93.65%
Regeneron-2.42%4.41%4.84%8.80%2.22%-18.14%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
BridgeBio Pharma110.85%452.73%33.29%102.48%102.48%102.48%
Regeneron-42.36%-20.46%-2.38%13.78%1,988.02%6,243.23%

News Based Sentiment: BridgeBio Pharma vs Regeneron

BridgeBio Pharma

News based Sentiment: MIXED

October presented a mixed bag for BridgeBio, with exceptional revenue growth and positive clinical data offset by an earnings miss and insider selling. While the stock reached a 52-week high, the conflicting signals create a complex investment picture, making this a significant month for the company's trajectory.

View BridgeBio Pharma News Sentiment Analysis

Regeneron

News based Sentiment: POSITIVE

October proved to be a positive month for Regeneron, marked by key FDA approvals for Lynozyfic and Evkeeza, encouraging trial results for their obesity pipeline, and positive analyst coverage from JP Morgan and Morningstar. While the Eylea biosimilar settlement introduces a future challenge, the overall narrative points towards continued growth and potential value for investors.

View Regeneron News Sentiment Analysis

Performance & Financial Health Analysis: BridgeBio Pharma vs Regeneron

MetricBBIOREGN
Market Information
Market Cap i$10.45B$63.78B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i1,895,5901,129,150
90 Day Avg. Volume i2,262,6601,040,977
Last Close$54.61$585.48
52 Week Range$21.72 - $54.64$476.49 - $1,024.36
% from 52W High-0.05%-42.84%
All-Time High$73.50 (Feb 08, 2021)$1,211.20 (Aug 26, 2024)
% from All-Time High-25.70%-51.66%
Growth Metrics
Quarterly Revenue Growth50.00%0.04%
Quarterly Earnings Growth50.00%-0.03%
Financial Health
Profit Margin (TTM) i0.98%0.31%
Operating Margin (TTM) i-1.21%0.30%
Return on Equity (TTM) i0.37%0.15%
Debt to Equity (MRQ) i-1.049.04
Cash & Liquidity
Book Value per Share (MRQ)$-9.35$287.55
Cash per Share (MRQ)$3.96$72.04
Operating Cash Flow (TTM) i$-655,808,000$4.74B
Levered Free Cash Flow (TTM) i$-297,633,248$2.85B
Dividends
Last 12-Month Dividend Yield iN/A0.46%
Last 12-Month Dividend iN/A$2.64

Valuation & Enterprise Metrics Analysis: BridgeBio Pharma vs Regeneron

MetricBBIOREGN
Price Ratios
P/E Ratio (TTM) i-18.3515.13
Forward P/E i-17.2713.24
PEG Ratio i-0.13-200.46
Price to Sales (TTM) i42.854.47
Price to Book (MRQ) i-5.662.09
Market Capitalization
Market Capitalization i$10.45B$63.78B
Enterprise Value i$11.22B$57.45B
Enterprise Value Metrics
Enterprise to Revenue i47.564.04
Enterprise to EBITDA i-17.9812.86
Risk & Other Metrics
Beta i1.360.31
Book Value per Share (MRQ) i$-9.35$287.55

Financial Statements Comparison: BridgeBio Pharma vs Regeneron

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)BBIOREGN
Revenue/Sales i$116.63M$3.03B
Cost of Goods Sold i$2.64M$464.30M
Gross Profit i$113.99M$2.56B
Research & Development i$111.43M$1.34B
Operating Income (EBIT) i$-103.80M$591.70M
EBITDA i$-104.46M$900.90M
Pre-Tax Income i$-169.61M$905.00M
Income Tax iN/A$96.30M
Net Income (Profit) i$-169.61M$808.70M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)BBIOREGN
Cash & Equivalents i$540.60M$3.09B
Total Current Assets i$695.17M$17.57B
Total Current Liabilities i$152.11M$3.57B
Long-Term Debt i$1.85B$2.70B
Total Shareholders Equity i$-1.64B$29.39B
Retained Earnings i$-3.26B$32.38B
Property, Plant & Equipment i$13.86MN/A

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)BBIOREGN
Operating Cash Flow i$-215.45M$1.36B
Capital Expenditures i$0N/A
Free Cash Flow i$-200.83M$773.60M
Debt Repayment i$-459.00MN/A
Common Stock Repurchase i$-50.05M$-1.05B

Short Interest & Institutional Ownership Analysis

MetricBBIOREGN
Shares Short i19.44M2.99M
Short Ratio i8.653.06
Short % of Float i0.17%0.03%
Average Daily Volume (10 Day) i1,895,5901,129,150
Average Daily Volume (90 Day) i2,262,6601,040,977
Shares Outstanding i190.04M109.62M
Float Shares i151.36M97.89M
% Held by Insiders i0.05%0.02%
% Held by Institutions i1.02%0.90%

Dividend Analysis & Yield Comparison: BridgeBio Pharma vs Regeneron

MetricBBIOREGN
Last 12-Month Dividend iN/A$2.64
Last 12-Month Dividend Yield iN/A0.46%
3-Year Avg Annual Dividend iN/A$0.88
3-Year Avg Dividend Yield iN/A0.14%
3-Year Total Dividends iN/A$2.64
Ex-Dividend DateN/AAug 18, 2025